Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a device zap chemo nerve pain? new trial aims to find out

NCT ID NCT07219472

Symptom relief Sponsor: Case Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This study tests whether scrambler therapy, a device that sends electrical signals to the skin, can reduce pain, numbness, and tingling from chemotherapy-induced peripheral neuropathy. About 90 adults with persistent nerve pain will receive either real or sham treatment for 10 sessions. Researchers will track changes in pain and quality of life over a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Scrambler Therapy device
What this could lead to
If it works, this could offer a non-drug option to reduce pain and improve daily life for people with chemotherapy-induced nerve damage.
What could go wrong
This is a small, early-stage study with only 90 people. The sham control means some may not get real treatment, and results may not apply to everyone with nerve pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults with CIPN-related pain for at least three months duration, and for which the participant wants intervention * At least three months from the last dose of neurotoxic cancer-directed drug * No plan (at the time of study enrollment) for additional neurotoxic cancer-directed therapies for at least five months after trial enrollment * Pain rated ≥ four out of 10 in severity (0-10 pain scale) during the seven days prior to enrollment * \> Six-month life expectancy * Able to complete questionnaires by themselves or with assistance * Able to provide informed written consent * ECOG Performance Status score ≥ two * Not currently enrolled in another research study for pain or neuropathy Exclusion Criteria: * Pregnant or nursing * An operational implanted drug delivery system, implanted electronic medical device, life supporting medical device, and/or medical monitoring device * History of myocardial infarction or ischemic heart disease within six months of trial enrollment * History of epilepsy, brain damage resulting in seizure activity, or use of anticonvulsants for seizure * Skin conditions such as open sores that will prevent proper application of electrodes * Unwillingness or inability to wean and discontinue gabapentin or pregabalin prior to the start of ST * History of symptomatic peripheral neuropathy prior to receiving neurotoxic chemotherapy * Prior treatment with Scrambler Therapy * The presence of chronic regional pain syndrome (CRPS) in the scrambler therapy treatment area.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy-induced peripheral neuropathy Cipn - chemotherapy-induced peripheral neuropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

    RECRUITING

    Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.